IL-1 beta Monoclonal Antibody (ILB1-H6), Biotin, Invitrogen™

Description

• M420BB targets IL-1 beta in ELISA applications and shows reactivity with Human samples
• The M420BB immunogen is recombinant human IL-1 beta
• M420BB detects IL-1 beta which has a predicted molecular weight of approximately 31 kDa
• The M420BB IL1b antibody (biotinylated conjugate of clone ILB1-H6) has successfully been paired as the detection antibody in a sandwich ELISA with capture antibody M421B (clone ILB1-H67)
• Typical dilutions for sandwich ELISA include 1 μg/mL for coating and 0.125 - 0.25 μg/mL for detection
• Biotinylated antibody M420BB (clone ILB1-H6) and antibody M421B (clone ILB1-H67) have successfully been used in combination with recombinant IL1 beta protein SIL1B in ELISA applications
• Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells
• IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol
• Cleavage of pro-IL-1 beta into the active 17 kDa protein requires the activation of inflammasomes, which are multi-protein complexes that respond to pathogens, stress conditions, and other danger signals
• Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1 beta
• IL-1 beta lacks a signal sequence peptide for classical ER/Golgi pathway and is secreted alongside caspase-1 via an alternate and incompletely understood mechanism
• Although IL-1 beta is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions
• IL-1 beta signals through two receptors, IL-1RI and IL-1RII, both of which are shared with IL-1 alpha
• IL-1 beta activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition
• IL-1 beta play an important role in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses to infection and injury
• Elevated levels of IL-1 beta have been associated with many chronic inflammatory conditions IL-1 beta neutralizing antibodies potential therapeutic value.